Sensus Healthcare (NASDAQ:SRTS) Upgraded to "Hold" at Wall Street Zen

Wall Street Zen upgraded shares of Sensus Healthcare (NASDAQ:SRTS - Free Report) from a sell rating to a hold rating in a research report sent to investors on Saturday.

Several other research analysts have also recently issued reports on SRTS. HC Wainwright reissued a "buy" rating and issued a $12.00 price target on shares of Sensus Healthcare in a research note on Friday, April 4th. Lake Street Capital decreased their target price on Sensus Healthcare from $18.00 to $13.00 and set a "buy" rating for the company in a research note on Tuesday, March 11th. Finally, Maxim Group decreased their target price on Sensus Healthcare from $14.00 to $10.00 and set a "buy" rating for the company in a research note on Monday, May 19th. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Sensus Healthcare presently has an average rating of "Buy" and an average target price of $11.67.

Sensus Healthcare Stock Down 3.2%

NASDAQ SRTS traded down $0.16 during trading hours on Friday, hitting $4.81. The company had a trading volume of 46,468 shares, compared to its average volume of 195,385. Sensus Healthcare has a fifty-two week low of $4.01 and a fifty-two week high of $9.33. The business has a fifty day simple moving average of $4.66 and a 200-day simple moving average of $5.76. The firm has a market cap of $79.10 million, a P/E ratio of 12.03 and a beta of 1.32.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last issued its earnings results on Thursday, May 15th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.20). Sensus Healthcare had a return on equity of 12.60% and a net margin of 15.90%. The company had revenue of $8.34 million during the quarter, compared to analyst estimates of $7.23 million. Equities analysts forecast that Sensus Healthcare will post 0.32 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Sigma Planning Corp acquired a new position in shares of Sensus Healthcare in the 4th quarter valued at $215,000. IFP Advisors Inc acquired a new position in shares of Sensus Healthcare in the 4th quarter valued at $95,000. Virtu Financial LLC acquired a new position in shares of Sensus Healthcare in the 4th quarter valued at $189,000. JPMorgan Chase & Co. acquired a new position in shares of Sensus Healthcare in the 4th quarter valued at $27,000. Finally, Arrowstreet Capital Limited Partnership boosted its position in shares of Sensus Healthcare by 81.2% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 150,150 shares of the company's stock valued at $1,039,000 after purchasing an additional 67,269 shares during the period. Institutional investors own 25.30% of the company's stock.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.